知镜 Cognispect · 医学文献与研究工作台

Bezafibrate-associated rhabdomyolysis in a patient with diabetic kidney disease: A case report and successful transition to tafolecimab.

Zhang Y, Wang J, Xie X, Gu W.
Medicine · 2026-06-01 · PMID 42332483

文献摘要

Rationale Fibrates like bezafibrate are renally excreted and can cause rhabdomyolysis in chronic kidney disease (CKD). This report describes bezafibrate-associated rhabdomyolysis in a patient with diabetic kidney disease and successful transition to tafolecimab. Patient concerns Ten days after self-initiating bezafibrate (0.2 g thrice daily), a 71-year-old female patient with diabetes, hypertension, CKD, and dyslipidemia complained of fatigue, sweating, and myalgia. Tests revealed hypokalemia, renal failure (creatinine 329.3 μmol/L), and increased creatine kinase (4865 U/L). Diagnoses After ruling out other causes, a peak creatine kinase of 6419 U/L (38× upper normal limit) and myalgia were used to diagnose bezafibrate-associated rhabdomyolysis. Interventions The use of bezafibrate was stopped. Hepatoprotection, renal protection, bicarbonate, potassium correction, and eventually a switch to subcutaneous tafolecimab 150 mg every 2 weeks were all part of the supportive care. Outcomes Myalgia went away in 6 days, and by the time of discharge, creatine kinase had returned to normal from 6419 to 54 U/L. Following tafolecimab, low-density lipoprotein cholesterol (4.18 to 2.93 mmol/L) was lower, and muscle enzymes were normal. Lessons Bezafibrate may result in severe rhabdomyolysis in diabetic CKD, particularly when combined with nifedipine (a CYP3A4 inhibitor) and reduced renal clearance. Tafolecimab's nonrenal metabolism and low myotoxicity make it a safe and efficient substitute.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。